Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors

被引:4
|
作者
Inada, Y [1 ]
Nakane, T [1 ]
Chiba, S [1 ]
机构
[1] Shinshu Univ, Sch Med, Dept Pharmacol, Matsumoto, Nagano 390, Japan
关键词
angiotensin II; AT(1) receptor; AT(2) receptor; binding; insurmountable antagonism;
D O I
10.1046/j.1472-8206.2002.00076.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We studied the binding properties of KRH-594, a new selective antagonist of angiotensin II (AII) type 1 (AT(1)) receptors, to rat liver membranes and to recombinant AT(1) and AT(2) receptors. Preincubation of rat liver membranes with KRH-594 produced maximal inhibition of [I-125]-AII binding when the preincubation time was 1-2 h. Preincubation with KRH-594 for 2 h decreased the B-max value and increased the K-d value. For human AT(1), human AT(2), rat AT(1A) and rat AT(1B) receptors, the K-i values for KRH-594 were 1.24, 9360, 0.67, and 1.02 nm, respectively. The rank order of K-i values for human AT(1) receptors was KRH-594 >> EXP3174 > candesartan = AII. The order of specificities for human AT(1) and AT(2) receptors was candesartan > EXP3174 > KRH-594. Although a 2-h preincubation of human AT(2) receptors with KRH-594 (30 muM) or CGP 42112 (a selective AT(2) receptor antagonist; 0.3 nm) inhibited binding of [I-125]-AII, the suppression by KRH-594 was not significant. These results indicate that KRH-594 binds potently to AT(1) receptors in an insurmountable manner, and that at a very high dose (30 muM) it may also bind to AT(2) receptors, but in a surmountable manner.
引用
收藏
页码:317 / 323
页数:7
相关论文
共 50 条
  • [31] Angiotensin-II type 1 receptor polymorphism is associated with an increased vasoreactivity to angiotensin II in human arteries
    van Geel, PP
    Voors, AA
    Oosterga, M
    Pinto, YM
    Buikema, H
    Kingma, JH
    Crijns, HJGM
    van Gilst, WH
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) : 26A - 26A
  • [32] Modeling Angiotensin II-mediated activation of the Angiotensin II Type 1 Receptor
    Anderson, Shane D.
    Botello-Smith, Wesley M.
    Luo, Yun Lyna
    Andresen, Bradley T.
    FASEB JOURNAL, 2018, 32 (01):
  • [33] Mechanical stress activates angiotensin II type 1 receptor independent of angiotensin II
    Zou, YZ
    Akazawa, H
    Qin, YJ
    Sano, M
    Iwanaga, K
    Zhu, WD
    Takano, H
    Minamino, T
    Tamura, K
    Kihara, M
    Fukamizu, A
    Umemura, S
    Komuro, I
    CIRCULATION, 2004, 110 (17) : 192 - 192
  • [34] Intracellular Accumulation and Nuclear Trafficking of Angiotensin II and the Angiotensin II Type 1 Receptor
    Cook, Julia L.
    Re, Richard N.
    LOCAL CARDIAC RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM, SECOND EDITION, 2009, : 29 - 41
  • [35] Angiotensin II Type 1 Receptor Mediates Angiotensin II Inhibition on BKCa Channels
    Zhang, Zhu
    Lu, Rong
    Stefani, Enrico
    Toro, Ligia
    BIOPHYSICAL JOURNAL, 2012, 102 (03) : 691A - 691A
  • [36] LABELING THE ANGIOTENSIN II TYPE 1 RECEPTOR WITH A DOPA SUBSTITUTED ANGIOTENSIN II ANALOGUE
    Arsenault, J.
    Jarine, H.
    Guillemette, G.
    Leduc, R.
    Lavigne, P.
    Escher, E.
    BIOPOLYMERS, 2009, 92 (04) : 329 - 329
  • [37] Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer
    Miyajima, Akira
    Kikuchi, Eiji
    Kosaka, Takeo
    Oya, Mototsugu
    REVIEWS ON RECENT CLINICAL TRIALS, 2009, 4 (02) : 75 - 78
  • [38] Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors
    Verheijen, I
    Fierens, FLP
    DeBacker, JP
    Vauquelin, G
    Vanderheyden, PML
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2000, 14 (06) : 577 - 585
  • [39] Effects of angiotensin II type 1 receptor antagonist on rats with septic shock
    Guo, Jianrong
    Guo, Wei
    Jin, Xiaoju
    Liu, Yang
    Zhang, Lei
    Zhang, Jianping
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (05): : 7867 - 7871
  • [40] CV-11974: A nonpeptide angiotensin II type 1 receptor antagonist
    Kinugawa, K
    Kohmoto, O
    Serizawa, T
    Takahashi, T
    CARDIOVASCULAR DRUG REVIEWS, 1997, 15 (01): : 59 - 74